Long Term Methotrexate Therapy Beneficial for Juvenile Localized Scleroderma PDF Print E-mail
Wednesday, 20 February 2013 00:03
Researchers in Italy evaluated 65 patients with Juvenile Localized Scleroderma (JLS; or morphea) previously enrolled in a double blind, randomized control trial and treated for the first 3 months with oral methotrexate (MTX; 15 mg/m2 weekly) and prednisone (1 mg/kg daily, maximum 50 mg). Clinical evaluation, infrared thermography and computerized skin scores were used to evaluate lesions.

Patients were defined as responders if they satisfied criteria including no new lesions, skin score rate less than 1 and a decrease in lesion temperature by at least 10% compared with baseline. Maintaining responder status after stopping treatment for at least 6 months was classified as clinical remission (CR), and response maintained while taking MTX for at least 6 months defined CR on medication (CRM).

Fifty-eight patients (mean age, 9.4 years; 72.4% female) were followed up during a mean of 40.3 months; seven were lost to follow-up. Forty-eight patients were responders at the last follow-up, while 10 patients relapsed within 24 months of MTX initiation. Responders were evaluated every 3 to 4 months during a mean of 43 months. Thirty-five responders received MTX for a mean of 27.5 months and then maintained CR for 25.6 months or longer without MTX. Thirteen other responders were in CRM. Twenty-eight patients experienced mild MTX-related side effects, including nausea and headache, but maintained treatment.

Researchers cited difficulty in comparing data to previous studies because objective measures such as infrared thermography and computerized skin score were unavailable.

“Long-term maintenance MTX treatment is beneficial for localized scleroderma (morphea) in young patients and is generally well tolerated with rare occurrence of significant adverse events,” the researchers concluded. “We recommend an initial 3 months of combined MTX-corticosteroid therapy and MTX treatment duration of at least 24 months to ensure a prolonged and sustained disease remission for the majority of the patients.”

Source: Healio Dermatology (2013), "Long-term methotrexate therapy effectively treated juvenile localized scleroderma"; Original article can be viewed here.

 
More articles :

» Recent Study Shows 32 Million Americans Have Autoantibodies That Target Their Own Tissues

A recent NIH study says more than 32 million people in the United States have autoantibodies, which are proteins produced in the immune system that attack the body's tissues, defining a condition known as . It also looked at the prevalence of the...

» Insights on Autoimmune Diseases and their Impact on Women

In a recent press release by the , Dr. Vivian Pinn discussed the latest research on autoimmune diseases in two podcasts with Dr. Robert Carter. Your body's immune system protects you from disease and infection. But if you have an autoimmune disease,...

» What Works for Raynaud's Phenomenon With Ischemic Finger

Until further testing confirms or disproves the promise of an oral formulation of treprostinil that is making its way through the developmental pipeline for management of Raynaud’s phenomenon and the ischemic finger, rheumatologists will have to...

» New Genetic Path Targeted For Scleroderma Therapy

A genetic pathway previously known for its role in embryonic development and cancer has been identified as a target for systemic sclerosis, or scleroderma, therapy. The finding, discovered by a cross-disciplinary team led by John Varga, MD, John and...

» Researchers Testing Intense Pulsed Light As An Alternative Treatment for Telangiectatases

Telangiectatases are knot-like clusters of blood vessels on the skin which can occur in 30 to 50 per cent of patients with Systemic Sclerosis, also known as . Telangiectases tend to occur on the face, neck, and upper limbs and can cause...

» Immune Therapy Developed for Atherosclerosis

is when plaque builds up in the arteries; and it can cause serious problems in the heart. However new strategies are helping patients combat atherosclerosis; and could change the treatment landscape of heart disease, all together.It was in the...